biologic

Haegarda

C1 Esterase Inhibitor Subcutaneous (Human)

Loss of exclusivityJune 2029projected — 12-year biologic exclusivity estimate
CompanyCSL BehringView the full company profile on CliffBio

Drug detail

Brand nameHaegarda
Active ingredientC1 Esterase Inhibitor Subcutaneous (Human)
Strength2000IU
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2017
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Haegarda patent cliff — loss of exclusivity June 2029 | CliffBio